journal
Journals Therapeutic Advances in Muscul...

Therapeutic Advances in Musculoskeletal Disease

https://read.qxmd.com/read/37694186/the-burden-of-low-back-pain-in-children-and-adolescents-with-overweight-and-obesity-from-pathophysiology-to-prevention-and-treatment-strategies
#1
REVIEW
Luca Ambrosio, Giorgia Mazzuca, Alice Maguolo, Fabrizio Russo, Francesca Cannata, Gianluca Vadalà, Claudio Maffeis, Rocco Papalia, Vincenzo Denaro
Nonspecific low back pain (LBP) is one of the most common causes of disability, affecting all individuals at least once in their lifetime. Such a condition is also becoming increasingly frequent in the pediatric population, especially in children and adolescents with overweight/obesity. Furthermore, new-onset LBP during adolescence has been demonstrated to be a strong predictor of developing LBP later in life, contributing to poorer outcomes and increasing social and medical costs. Several causes and different mechanisms have been considered for the development of LBP in pediatric individuals affected by obesity...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37694185/anti-sclerostin-antibodies-a-new-frontier-in-fragility-fractures-treatment
#2
REVIEW
Giovanni Iolascon, Sara Liguori, Marco Paoletta, Giuseppe Toro, Antimo Moretti
Bone fragility is the determinant of the increased risk of minimal trauma fracture and must be treated with a multimodal approach that includes pharmacological therapy, physical exercise, and adequate nutrition. Pharmacological therapy, to date based on the administration of antiresorptive drugs, such as bisphosphonates and denosumab, or osteoanabolic drugs, such as teriparatide and abaloparatide, has shown to be effective in reducing the risk of fracture in osteoporotic patients. In the context of the cellular and molecular mechanisms that regulate bone metabolism, the discovery of the Wnt signaling pathway and its role in bone tissue homeostasis has allowed the identification of sclerostin as an inhibitor of osteoblastic activity and simultaneously as a stimulator of osteoclastic activity...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37694184/regenerative-medicine-for-early-osteoarthritis
#3
REVIEW
Gun-Il Im, Yves Henrotin
The concept of early osteoarthritis (OA) is based on the expectation that if found and treated in the early stage, the progression of the disease might be arrested before affected joints are irreversibly destroyed. This notion of early OA detection can also bear meaning for regenerative medicine (RM) which is purposed to cure a disease by regenerating the damaged tissue. RM can be a category of disease-modifying osteoarthritis drugs (DMOADs) and provide an attractive treatment for OA, restoring structural damage incurred during the disease by repopulating cells and reconstituting...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37694183/treatment-with-adalimumab-in-patients-with-chronic-inflammatory-rheumatic-diseases-a-study-of-treatment-trajectories-on-a-patient-level-in-routine-care
#4
JOURNAL ARTICLE
Imke Redeker, Stefan Moustakis, Styliani Tsiami, Xenofon Baraliakos, Ioana Andreica, Bjoern Buehring, Jürgen Braun, Uta Kiltz
BACKGROUND: Previous experiences with non-medical switching of adalimumab (ADA) in patients with chronic inflammatory rheumatic diseases (CIRD) come mainly from phase III extension of randomised clinical trials and little from routine care. OBJECTIVES: To analyse treatment trajectories over 2 years in patients with CIRD conducting a non-medical switch from originator to biosimilar ADA. DESIGN: A retrospective observational cohort study was conducted with data from a third-level rheumatology centre in Germany...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37694182/application-of-clinical-and-molecular-profiling-data-to-improve-patient-outcomes-in-psoriatic-arthritis
#5
REVIEW
Oliver FitzGerald, Frank Behrens, Anne Barton, Heidi Bertheussen, Bruno Boutouyrie-Dumont, Laura Coates, Owen Davies, Maarten de Wit, Filippo Fagni, Carl S Goodyear, Robert Gurke, Lisa Hahnefeld, Christine Huppertz, Vassilios Ioannidis, Mark Ibberson, Arnon Katz, Maximilian Klippstein, Michaela Koehm, Shimon Korish, Sina Mackay, David A Martin, Denis O'Sullivan, Khadijah Patel, Stefan Rueping, Georg Schett, Klaus Scholich, Jochen M Schwenk, Stefan Siebert, David Simon, Arani Vivekanantham, Stephen R Pennington
Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37663034/achievement-of-higher-thresholds-of-clinical-responses-and-lower-levels-of-disease-activity-is-associated-with-improvements-in-workplace-and-household-productivity-in-patients-with-axial-spondyloarthritis
#6
JOURNAL ARTICLE
Martin Rudwaleit, Pedro M Machado, Vanessa Taieb, Natasha de Peyrecave, Bengt Hoepken, Lianne S Gensler
BACKGROUND: Patients with active axial spondyloarthritis (axSpA) exhibit more absences and lower levels of productivity in the workplace and household than the general population, which can improve upon treatment. OBJECTIVES: The objective of this study is to determine the long-term impact of achieving different levels of clinical response or disease activity on workplace and household productivity in patients with axSpA. DESIGN: RAPID-axSpA (NCT01087762) was a 204-week phase III trial evaluating the safety and efficacy of certolizumab pegol (CZP) in adult patients with active axSpA...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37645684/the-effect-of-ixekizumab-on-axial-manifestations-in-patients-with-psoriatic-arthritis-from-two-phase-iii-clinical-trials-spirit-p1-and-spirit-p2
#7
JOURNAL ARTICLE
Atul Deodhar, Dafna Gladman, Rebecca Bolce, David Sandoval, So Young Park, Soyi Liu Leage, Peter Nash, Denis Poddubnyy
BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory condition predominantly affecting the peripheral joints. However, some patients with PsA can experience axial involvement which is manifested with back pain and associated with increased burden of illness. OBJECTIVES: The aim of this post hoc analysis was to determine the efficacy of ixekizumab (IXE) up to 52 weeks in reducing axial symptoms in PsA patients, presenting with axial manifestations...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37645683/dysfunctional-high-density-lipoprotein-in-chronic-inflammatory-rheumatic-diseases
#8
JOURNAL ARTICLE
Sabina Waldecker-Gall, Felix Seibert, Sebastian Bertram, Adrian Doevelaar, Jürgen Braun, Xenofon Baraliakos, Nina Babel, Christoph Waldecker, Linda Scharow, Nikolaos Pagonas, Timm H Westhoff
BACKGROUND: The mechanism explaining low cholesterol concentrations in chronic inflammatory rheumatic disease (CIRD) is incompletely understood. We hypothesized that chronic inflammation impairs the functionality of high-density lipoprotein (HDL), for example, by oxidative processes. OBJECTIVES: Assessment of oxidized HDL (HDLox ), a marker of dysfunctional HDL, in newly diagnosed patients with CIRD before and after initiation of immunosuppressive therapy and comparison of HDLox values of patients with CIRD to non-CIRD controls...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37565049/drug-switching-in-axial-spondyloarthritis-patients-in-germany-a-social-listening-analysis
#9
JOURNAL ARTICLE
Maria Kahn, Steffeni Papukchieva, Axel Fehr, Markus Eberl, Berenice Rösler, Justyna Veit, Benjamin Friedrich, Denis Poddubnyy
BACKGROUND: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and non-pharmacological treatment. Second line treatment involves biological disease-modifying antirheumatic drugs (bDMARDs) such as tumour necrosis factor and interleukin-17 inhibitors...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37539016/efficacy-and-safety-of-abatacept-in-patients-with-rheumatoid-arthritis-with-previous-malignancy
#10
JOURNAL ARTICLE
Yosuke Kunishita, Kento Ichikawa, Yuji Uzawa, Masaki Mitsuhashi, Yuji Yoshioka, Tadanobu Okubo, Shouhei Nagaoka
BACKGROUND: Abatacept (ABT) is known to lower infection risk than other biologics and is effective and safe in elderly patients with rheumatoid arthritis (RA). However, there were inconsistent reports on the impact of ABT on malignancies which are more common in the elderly and strongly related to prognosis. OBJECTIVES: This study aimed to evaluate the efficacy and safety of ABT in patients with RA with previous malignancy in clinical practice. DESIGN: A multicenter, retrospective study...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37529333/a-prognostic-immune-nutritional-index-can-predict-all-cause-mortality-in-patients-with-antineutrophil-cytoplasmic-antibody-associated-vasculitis
#11
JOURNAL ARTICLE
Sung Soo Ahn, Jung Yoon Pyo, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee
BACKGROUND: Studies have proposed that nutritional and immune-related markers are relevant with patient outcomes of various medical conditions and could be a useful indicator of patient prognostication. OBJECTIVES: This study investigated whether a prognostic immune nutritional index (PINI) at diagnosis could predict adverse clinical outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). DESIGN: A retrospective, single-centre observational cohort analysis of patients with AAV...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37529332/oral-enzyme-combination-with-bromelain-trypsin-and-the-flavonoid-rutoside-reduces-systemic-inflammation-and-pain-when-used-pre-and-post-operatively-in-elective-total-hip-replacement-a-randomized-exploratory-placebo-controlled-trial
#12
JOURNAL ARTICLE
Jiří Vosáhlo, Adam Salus, Michael Smolko, Barbora Němcová, Veit Nordmeyer, Milos Mikles, Stefanie M Rau, Odd Erik Johansen
BACKGROUND: Early mobilization after total hip replacement (THR) is key for fast recovery but is often limited by pain. Oral enzyme combinations (OECs) have demonstrated anti-inflammatory and pain-relieving effects. OBJECTIVES AND DESIGN: This prospective, randomized, double-blind, placebo-controlled exploratory trial evaluated the effects of pre- and post-operative use of OEC (90 mg bromelain, 48 mg trypsin, 100 mg rutoside) following elective THR, on post-operative recovery...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37529331/new-insights-in-lower-limb-reconstruction-strategies
#13
REVIEW
Giuseppe Toro, Antonio Benedetto Cecere, Adriano Braile, Annalisa De Cicco, Sara Liguori, Umberto Tarantino, Giovanni Iolascon
High Energy Musculoskeletal Traumas (HEMTs) represent a relevant problem for healthcare systems, considering the high social costs, and both the high morbidity and mortality. The poor outcomes associated with HEMT are related to the high incidence of complications, including bone infection, fracture malunion and non-union. The treatment of each of these complications could be extremely difficult. Limb reconstruction often needs multiple procedures, rising some questions on the opportunity in perseverate to try to save the affected limb...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37529330/utilising-a-non-surgical-intervention-in-the-knee-osteoarthritis-care-pathway-a-6-year-retrospective-audit-on-nhs-patients
#14
JOURNAL ARTICLE
Robyn Benn, Lewis Rawson, Amanda Phillips
BACKGROUND: Knee osteoarthritis (OA) is a chronic, debilitating, musculoskeletal condition that affects millions. The increase in prevalence and its economic impact on healthcare and society raise the need for additional non-surgical interventions. OBJECTIVE: To assess the referral rates to secondary care consultation and clinical outcomes in patients with severe knee OA treated with a home-based, non-surgical intervention. DESIGN: This was a retrospective audit on 571 patients with knee OA who met the clinical criteria for total knee replacement (TKR) and received the service between October 2015 and March 2020...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37492226/retraction-notice
#15
(no author information available yet)
[This retracts the article DOI: 10.1177/1759720X21995069.].
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37484926/myths-and-truths-on-biophysics-based-approach-in-rehabilitation-of-musculoskeletal-disorders
#16
REVIEW
Alessandro de Sire, Lorenzo Lippi, Nicola Marotta, Martina Ferrillo, Arianna Folli, Alessio Turco, Antonio Ammendolia, Marco Invernizzi
Musculoskeletal disorders (MSD) are a crucial issue in current literature due to their impact on physical function, social, and economic costs. Rehabilitation plays a pivotal role in the therapeutic management of these disabling conditions with growing evidence underlining positive effects in improving functional outcomes. However, to date, several questions are still open about the mechanisms underpinning functional improvements while recent research is now focusing on a deeper understanding of the biophysical processes underpinning the macroscopical effects of these treatments...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37484925/reduced-bone-mineral-density-in-patients-with-idiopathic-inflammatory-myopathies-a-case-control-study
#17
JOURNAL ARTICLE
Iris Yan Ki Tang, Lucas Luk, Victor Wong, Steve Pang, Virginia Lao, Ho So
BACKGROUND: Patients with idiopathic inflammatory myopathies (IIMs) are at risk of reduced bone mineral density (BMD). OBJECTIVES: To compare the prevalence of reduced BMD between patients with IIMs and controls and to determine its risk factors. DESIGN: This was a single-center case-control study. METHODS: BMD was assessed by dual-energy X-ray absorptiometry. The prevalence of reduced BMD in IIM patients and age-and sex-matched non-rheumatological controls was compared...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37484924/mechanisms-hypothesized-for-pain-relieving-effects-of-exercise-in-fibromyalgia-a-scoping-review
#18
JOURNAL ARTICLE
Yuva Venkata Raghava Neelapala, Domenico Mercuri, Luciana Macedo, Steven Hanna, Dylan Kobsar, Lisa Carlesso
BACKGROUND: Exercise is one of the most recommended management strategies by treatment guidelines for fibromyalgia (FM); however, the mechanism through which exercise improves pain in FM is still unknown. OBJECTIVE: We aimed to summarize the hypothesized theoretical mechanisms for the pain-relieving effects of exercise in people with FM. ELIGIBILITY CRITERIA: Randomized controlled trials (RCTs) in English reporting mechanisms for pain-relieving effects of exercise in the 'Introduction' and 'Discussion' sections and significant within- group or between-group effects of exercise interventions were included...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37465567/clinical-characteristics-of-myositis-patients-with-isolated-anti-u1-ribonucleoprotein-antibody-resemble-immune-mediated-necrotizing-myopathy
#19
JOURNAL ARTICLE
Yongpeng Ge, Hongxia Yang, Wei Jiang, Xiaolan Tian, Xin Lu, Guochun Wang
BACKGROUND: Anti-U1 ribonucleoprotein (U1RNP) antibodies were associated with connective tissue diseases (CTDs), but the clinical characteristics of this antibody in Chinese myositis patients have not been studied. OBJECTIVE: We aim to analyze the clinical features of myositis patients who test positive for anti-U1RNP antibodies and delineate a subgroup of myositis. DESIGN: This is a retrospective cohort study. METHODS: We reviewed the clinical data of myositis patients with anti-U1RNP antibodies and compared them to those with anti-signal recognition particle (SRP) and hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibody-associated immune-mediated necrotizing myopathy (IMNM)...
2023: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/37457557/comparative-validation-of-the-knee-inflammation-mri-scoring-system-and-the-mri-osteoarthritis-knee-score-for-semi-quantitative-assessment-of-bone-marrow-lesions-and-synovitis-effusion-in-osteoarthritis-an-international-multi-reader-exercise
#20
Walter P Maksymowych, Jacob L Jaremko, Susanne J Pedersen, Iris Eshed, Ulrich Weber, Andrew McReynolds, Paul Bird, Stephanie Wichuk, Robert G Lambert
BACKGROUND: Bone marrow lesions (BMLs) and synovitis on magnetic resonance imaging (MRI) are associated with symptoms and predict degeneration of articular cartilage in osteoarthritis (OA). Validated methods for their semiquantitative assessment on MRI are available, but they all have similar scoring designs and questionable sensitivity to change. New scoring methods with completely different designs need to be developed and compared to existing methods. OBJECTIVES: To compare the performance of new web-based versions of the Knee Inflammation MRI Scoring System (KIMRISS) with the MRI OA Knee Score (MOAKS) for quantification of BMLs and synovitis-effusion (S-E)...
2023: Therapeutic Advances in Musculoskeletal Disease
journal
journal
42615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.